There are currently 927 clinical trials in Minneapolis, Minnesota looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Minnesota, Hennepin County Medical Center, Abbott Northwestern Hospital and University of Minnesota/Masonic Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
MYLUNG Consortium Part 3: Observational Study
NCT05885698
Recruiting
This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function
NCT06496217
Recruiting
Evaluate the Safety and Pharmacokinetics of MBX 2109 in Adult Subjects with Normal and Impaired Renal Function
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/17/2024
Locations: MBX Biosciences Investigational Site, Minneapolis, Minnesota
Conditions: Renal Impairment
Register for Updates
Control Network Neuromodulation to Enhance Cognitive Training in Complex Traumatic Brain Injury
NCT05236010
Recruiting
The CONNECT-TBI Trial aims to develop safe, effective treatments for complex mTBI that improve cognitive functioning. Based on the compelling preliminary data generated by our study team, the objective of this study is to conduct a randomized, double-blinded, sham-controlled Phase II clinical trial of APT-3 combined with rTMS, HD-tDCS, or sham to treat cognitive control deficits in Veterans with complex mTBI and PPCS. At the Baseline Visit, participants will undergo demographic, neuropsychologic... Read More
Gender:
ALL
Ages:
Between 18 years and 59 years
Trial Updated:
07/10/2024
Locations: Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota +1 locations
Conditions: Traumatic Brain Injury
Register for Updates
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
NCT04486352
Recruiting
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/02/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Endometrial Cancer
Register for Updates
TMS + Exposure Therapy for Pediatric OCD
NCT05931913
Recruiting
The goal of this clinical trial is to compare different forms of transcranial magnetic stimulation (TMS) for improving the outcomes of Exposure with Response Prevention (ERP) in youth and young adults with Obsessive-Compulsive Disorder (OCD). Researchers will compare three groups: ERP with one of two different active ("real") forms of TMS vs. ERP with sham ("fake") TMS. The main questions this study aims to answer are: 1) whether TMS normalizes functioning in brain circuits that contribute to co... Read More
Gender:
ALL
Ages:
Between 12 years and 21 years
Trial Updated:
07/01/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Obsessive-Compulsive Disorder
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Abbott-Northwestern Hospital, Minneapolis, Minnesota +3 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
NCT03053193
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Minnesota Oncology, Minneapolis, Minnesota
Conditions: Breast Cancer
Register for Updates
Evaluation of Left Bundle Branch Area Pacing As A Rescue Strategy for Cardiac Resynchronization Therapy Non-Response
NCT05884411
Recruiting
This study aims to investigate whether the investigators can improve heart function in patients with heart failure who have undergone cardiac resynchronization therapy, but have not had an improvement in their heart function at least one year after the procedure. The investigators will evaluate whether placing a new pacing lead (electrode) in a different part of the heart may increase heart function and decrease heart failure symptoms.
Gender:
ALL
Ages:
All
Trial Updated:
06/21/2024
Locations: Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota
Conditions: Systolic Heart Failure, Heart Failure With Reduced Ejection Fraction, CRT Non-Response, Left Bundle Branch Area Pacing
Register for Updates
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
NCT05948475
Recruiting
This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: University of Minnesota- Masonic Cancer Center, M Health Fairview, Minneapolis, Minnesota
Conditions: Cholangiocarcinoma
Register for Updates
EXHIT ENTRE Implementation Trial of High Intensity Versus Low Intensity Strategy
NCT04921787
Recruiting
This study is a multi-site, cluster randomized, two group implementation trial comparing a low- versus high-intensity implementation strategy for supporting hospital-based opioid use disorder treatment (HBOT) in community hospital settings where medication for opioid use disorder (MOUD) treatment has not been implemented.
Gender:
ALL
Ages:
All
Trial Updated:
06/14/2024
Locations: Hennepin Healthcare Research Institute, Minneapolis, Minnesota
Conditions: Substance Use Disorders, Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate
Register for Updates
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
NCT05181826
Recruiting
To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: VPCI Oncology Research, Minneapolis, Minnesota
Conditions: Cancer, Liver Cirrhosis, Chronic Hepatitis, Hepatitis B, Hepatitis C, Diabetes, COPD
Register for Updates
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
NCT05610085
Recruiting
The main purpose of this study is to determine the maximum safe tolerated dose of LEV in the treatment of neonatal seizures. Our hypothesis is that optimal dosing of Levetiracetam (LEV) to treat neonatal seizures is significantly greater than 60mg/kg. This study will be an open label dose-escalation, preliminary safety and efficacy study. There will be a randomized control treatment component. Infants recognized as having neonatal seizures or as being at risk of developing seizures will be recru... Read More
Gender:
ALL
Ages:
1 month and below
Trial Updated:
06/10/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Neonatal Seizure, Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy, Seizure Newborn
Register for Updates